Moderna is leading the charge to create new solutions for patients based on messenger RNA Therapeutics™. Our mandate is to deliver safe and efficacious medicines, and we are actively seeking partners to join us in this mission, as we cannot deliver on every potential application of our technology alone. Our science offers an accelerated path of drug discovery for some of the world’s most complex and deadly diseases; we have a clear means to quickly generate proof-of-concept data in a wide range of human illness; and our approach raises exciting possibilities for rare diseases in particular. We are actively seeking partnerships with pharmaceutical and biotechnology companies, patient organizations, and research institutions who are passionate about developing new treatments that will make a difference in the lives of patients. We are interested in hearing from organizations who have gathered disease-specific knowledge and data, to discuss how we can transform those resources into a clinical program to benefit patients.
In January 2014, we announced an exclusive strategic agreement for the discovery and development of messenger RNA Therapeutics™ to treat rare diseases.
Under the agreement, Alexion will purchase 10 product options to develop and commercialize treatments for rare diseases with Moderna’s mRNA Therapeutics™ platform.
Following option exercise by Alexion, Moderna will be entitled to drug development and commercial milestone payments, as well as high single to double digit royalties on commercial sales.
Alexion will lead the discovery, development and commercialization of the treatments produced through this broad, long-term strategic agreement, while Moderna will retain responsibility for the design and manufacture of the messenger RNA against selected targets.
In March 2013 we signed a five-year strategic option agreement with AstraZeneca to discover and develop messenger RNA Therapeutics™. Under the agreement, AstraZeneca has exclusive access to Moderna’s mRNA therapeutic platform in the area of cardiometabolic diseases, as well as selected oncology targets.
Moderna will be responsible for designing and manufacturing the messenger RNA against selected targets, and AstraZeneca will lead the preclinical development, clinical development, and commercialization of messenger RNA Therapeutics™ resulting from the collaboration.
In addition to an upfront cash payment and three technical cash milestones, Moderna will be entitled to receive development and commercial cash milestones, as well as royalty payments, for up to forty medicines.
Let’s talk. Contact: firstname.lastname@example.org